Now Available: Imoxi™ (imidacloprid + moxidectin) Topical Solution for Dogs

New generic broad spectrum, cost-effective option to protect against heartworm, control fleas, and intestinal parasites.

FORT WORTH, TEXAS (July 12, 2021) – Vetoquinol USA announces the launch of Imoxi™ (imidacloprid + moxidectin) Topical Solution for Dogs.

"We are excited that Vetoquinol's first entry into the parasiticides market brings veterinarians and pet owners broad-spectrum parasite protection at an affordable cost," said Eric M. Alsup, DVM, Country Manager, Vetoquinol USA. "Imoxi provides the combination of imidacloprid and moxidectin that veterinarians trust, but at a cost more owners can afford."

In a study, lack of compliance in administering heartworm preventives was a possible reason for rising incidence of heartworm cases from 2013 to 2016.¹ One survey found the cost of heartworm treatment was a major barrier to dog owners not currently using any preventive products.²

Imoxi is a once-a-month topical formula trusted for broad-spectrum protection against fleas, heartworm, sarcoptic manage, and intestinal parasites. It is available in a ready-to-use solution and is approved for use on puppies that are at least 7 weeks of age and dogs weighing at least 3 pounds.

Imoxi is available to pet owners by prescription only. Veterinarians can purchase now through select distributors or by contacting their Vetoquinol representative.

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs: WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings and Adverse Reactions for more information.) Cats: Do not use on sick, debilitated, or underweight cats. Avoid oral ingestion. For full prescribing information, visit www.vetoquinolusa.com/imoxi-info.

About Vetoquinol USA

Headquartered in Fort Worth, Texas, Vetoquinol USA is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of FDA, EPA, NASC, and AAFCO-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.

Contact
Jennifer Ryan
(620) 388-3937
usa_news@vetoquinol.com

References:
1. Drake, J. and Wiseman, S. (2018) Increasing incidence of Dirofilaria immitis in dogs in USA with focus on the southeast region 2013–2016. Parasites & Vectors, 11:39.
2. Veterinary Practice News. (2019 September 5) Heartworm prevention: Clients can’t comply if they don’t know that they should. https://www.veterinarypracticenews.com/heartworm-prevention-clients-cant-comply-if-they-dont-know-that-they-should/. Accessed May 25, 2021.

©2021 Vetoquinol USA, Inc. Vetoquinol, the Vetoquinol logo, and Imoxi are registered trademarks of Vetoquinol USA, Inc.

IMX-0352-DOGPR